Swiss-based Accelleron was formed from the spin-off of ABB’s highly profitable turbocharger division in 2022. We view the share as a promising investment on 1/ market leadership in an attractive niche, 2/ about ~40% ROCE, 3/ conversion of ~80% of EBITDA into cash, leading to fast deleveraging, and a solid base for shareholder remuneration (75% pay out), and 4/ strong long-term visibility linked to a ~75% service share, the bulk of which is recurring. Despite an already strong stock pe...
>Life Sciences – the turnaround for Process solutions - While there is still some residual headwind related to destocking and the changing ordering pattern of customers, the 3.7% organic growth in Q3 was a clear positive surprise. The company highlighted that sales and order intake increased sequentially q-o-q. For the fourth quarter, additional sequential growth was indicated not only in absolute terms, but also as organic growth rate. We assume 5% organic growth for...
>Q3 review – beat on EBITDA pre level, guidance confirmed - Merck’s Q3 revenues of € 5,266m (+1.8% y-o-y) were driven by organic growth of 3.8% and were 0%/-1% vs ODDO BHF/consensus. On the bottom line, the company reported EBITDA pre of € 1,618m (+11.9% y-o-y, margin 30.7%), 5% ahead of expectations. EPS pre reached € 2.30, in line with expectations. The 2024 guidance was confirmed with revenues in the range of € 20.7bn to € 22.1bn, trending towards the lower half of...
>Focus on lower capital intensity over the next years - Following some years of elevated capex projects, CFO Helene von Roeder indicated lower capital expenditure in absolute terms that support an improving cash conversion backed also by an improving sales mix. As a result, free cash flow is expected to improve. Regarding the allocation of capital for potential acquisitions, a substantial amount is allocated towards the Life Sciences segment. For Healthcare, a de-risk...
Moody's Ratings (Moody's) has today assigned a Baa2 junior subordinated rating to the proposed €800 million fixed to reset rate notes due 2054 (the hybrid) issued by Merck KGaA (Merck or the company). The outlook is stable. Merck intends to use the proceeds of the new hybrid issuance, for general ...
>Second quarter with strong quarter for Healthcare and Electronics - Merck had already reported, on 26 July, preliminary Q2 results ahead of expectations with revenues of € 5,352m (+0.9% y-o-y). On the bottom line, the company reported EBITDA pre of € 1,509m (-2.9% y-o-y, margin 28.2%). EPS pre reached € 2.20. The company now expects revenues in the range of € 20.7bn to € 22.1bn (previously € 20.6bn to € 22.1bn), which compares to our new forecast of € 21.4bn. On EBIT...
>Top and bottom-line results on group level already reported - Merck had already reported, on 26 July, preliminary Q2 results ahead of expectations with revenues of € 5,352m (+0.9% y-o-y). On the bottom line, the company reported EBITDA pre of € 1,509m (-2.9% y-o-y, margin 28.2%). EPS pre reached € 2.20. The company now expects revenues in the range of € 20.7bn to € 22.1bn (previously € 20.6bn to € 22.1bn) On EBITDA pre, Merck now sees a range of € 5.8bn to € 6.4bn (p...
Questions are mounting for the equity markets on multiple fronts: economic (turbulence or slowdown), monetary (how quickly will central banks cut rates) and geopolitical (France, US, Russia/Ukraine, China). For the rest of the summer, we are maintaining our positive bias on US vs European equities. On European equities, we are returning to a neutral stance between cyclicals and defensives, between value and growth styles, between large caps and small caps, and recommend increasing pos...
Les questions s’accumulent pour les marchés actions : sur les plans économique (trou d’air ou ralentissement ?), monétaire (à quel rythme les banques centrales vont-elles baisser les taux) et (géo)politique (France, Etats-Unis, Russie/Ukraine, Chine). Pour le reste de cet été, nous conservons notre biais positif sur les actions américaines vs européennes. Sur les actions européennes, nous revenons à la neutralité entre cycliques et défensives, entre les styles Value et Growth, entre L...
>Preliminary results driven by Healthcare and Electronics - Merck reported preliminary Q2 results with revenues of € 5,352m (+0.9% y-o-y), which were 1% ahead of our forecast and 2% ahead of consensus. While the company did not provide results on a segmental base, the better than expected performance was driven by the Healthcare and the Electronics division. The development of the Life Science division was described as within expectations. On the bottom line, the comp...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.